GeneDx Holdings Corp

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GeneDx reports robust growth, eyes profitability by 2025

GeneDx's strong financial performance in 2022 and growth projections for 2023 indicate a promising trajectory for the company.
Strategic shifts towards whole genome sequencing, fundraising success, and favorable market coverage position GeneDx well for future success.
While facing challenges in business transitions and financial management, GeneDx has opportunities to drive profitability through margin expansion and strategic partnerships.

GeneDx reports robust Q1 earnings, eyes profitability by 2025

GeneDx's Q1 2023 performance reflects strong revenue growth and strategic positioning for future profitability by 2025.
The company's focus on rare disease testing, pediatric settings, and genome testing, coupled with financial improvements, highlights its resilience.
Challenges include managing cash burn, navigating competition, and balancing cost reduction with growth investments.
Opportunities for GeneDx include expanding market share, strategic partnerships, innovation in testing, and comprehensive patient care.

GeneDx reports record revenue and market dominance in genomics

GeneDx's strong performance in Q2 2023 reflects robust revenue growth and market dominance in exome and genome testing. The company's strategic focus on cost optimization, revenue enhancement, and market expansion positions it well for future profitability and growth.

GeneDx reports robust Q3 results, targets profitability by 2025

GeneDx Holdings Corp shows strong performance in Q3 2023 with revenue of $53 million and improved gross margins, supported by a cost reduction plan and debt facility.
While facing challenges in claim denials and lengthy appeal processes, the company aims to drive revenue growth from exome and genome testing to achieve profitability by 2025.
Opportunities lie in capital allocation for growth initiatives and sustainable profitability through cost reduction efforts and strategic investments in R&D.

GeneDx reports strong Q4 results, targets profitability by 2025

GeneDx demonstrated robust financial performance in Q4 2023, with revenue growth, improved margins, and reduced cash burn, setting a positive trajectory for future profitability.
Strategic initiatives like realigned sales strategy and focus on exome and genome tests position GeneDx for sustained growth and increased profitability in the coming years.
While challenges exist in managing cash burn and achieving profitability targets, GeneDx's strong financial position, strategic partnerships, and market focus offer opportunities for continued success.

GeneDx's strong financial performance, strategic strengths, and growth opportunities position it well for future success and profitability.
While facing challenges such as high denial rates and the path to profitability, the company's proactive approach and market focus offer avenues for improvement.
By leveraging its competitive advantages, addressing challenges, and capitalizing on growth opportunities, GeneDx aims to sustain its growth trajectory and achieve profitability by 2025.

GeneDx reports robust Q2 earnings, eyes profitability amid market expansion

GeneDx Holdings Corp's Q2 2024 performance reflects strong revenue growth, margin expansion, and progress towards profitability.
The company's strengths lie in its focus on pediatric genetics, successful product mix transition, and strategic investments in genome sequencing.
Challenges include policy expansion hurdles, maintaining financial discipline, and achieving profitability amidst industry dynamics.
Opportunities for GeneDx include market expansion through partnerships, patient access programs, and operational efficiency enhancements.

GeneDx reports robust Q3 earnings, eyes growth in genetic testing

GeneDx Holdings Corp delivered a strong Q3 performance, achieving profitability and raising revenue guidance for the year.
The company's strategic strengths lie in its market leadership, advanced sequencing capabilities, and diversified revenue streams.
While facing challenges in balancing growth and innovation, GeneDx has opportunities to expand into new markets and drive long-term success.
By optimizing costs, focusing on efficiency, and investing strategically, GeneDx aims to maintain profitability and drive innovation in genetic testing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 43rd Annual J.P. Morgan Healthcare Conference from January 12-16 in San Francisco, CA. Management will participate in a presentation on Wednesday, January 15, 2025, at 4:30 p.m. PT. Live and archived webcasts will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.

GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Biogen

Praxis Precision Medicines

Stoke Therapeutics Inc

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx today announced Biogen, Praxis Precision Medicines and Stoke Therapeutics as the founding partners to its Patient Access Program for epilepsy.

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

Biotech stock GeneDx soared 50% after earnings on Oct. 29. Shares of the genetic testing company have soared 2,762% year to date.

This Once Ultracheap Biotech Stock Rockets 2,762%, Nears Buy Point After Big Earnings Win

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that company management will participate in the Piper Sandler 36th Annual Healthcare Conference.

GeneDx to Participate in Upcoming Investor Conference

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced GeneDx Discover, a first-of-its-kind data visualization tool, which provides biopharmaceutical companies access to deidentified and aggregated genetic data - powered by GeneDx's robust database - to improve all stages of drug development. The new offering is part of GeneDx's ongoing investment to deliver personalized and actionable health insights to.

GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Heidi Chen as Chief Legal Officer, effective November 25, 2024. In her role, Heidi will report to Katherine Stueland, CEO and President, and will serve on the executive leadership team. With over 30 years of experience, Heidi will lead all legal, compliance, and policy functions at GeneDx and will provide strategic counsel on corpor.

GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary

Meet the Healthcare Stock That Produced Nvidia-Sized Gains in Less Than a Year

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the results of an extensive study shedding light on the critical issue of racial disparities in access to an accurate genetic diagnosis. The study, a collaboration among GeneDx, The University of Washington, Brotman Baty Institute for Precision Medicine, Geisinger and Seattle Children's Hospital, was conducted on nearly 187,000 samples performed and a.

New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 American Society of Human Genetics (ASHG) annual meeting. GeneDx data will be presented across six platform presentations and five posters and will unveil findings from key research initiatives constructed on the backbones of its industry leading diverse dataset of more than 700,000 clinical exome and genomes.

GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting

Leonardo DRS Inc

Snap

Stocks like Snap, GeneDx Holdings and Leonardo DRS exhibit solid earnings acceleration.

3 Stocks to Buy for Stellar Earnings Acceleration in November

Carvana

NB Bancorp Inc

WGS, CVNA and NBBK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 4, 2024.

Best Momentum Stocks to Buy for November 4th

Capitol Federal Financial

Controladora Vuela Cia de Aviacion SAB de CV

CFFN, VLRS, NBBK, WGS and ISBA have been added to the Zacks Rank #1 (Strong Buy) List on November 4, 2024.

New Strong Buy Stocks for November 4th

The precision medicine market is projected to grow from $91.72 billion in 2024 to $246.3 billion by 2033, fueled by advancements in genomic technologies. In the last year, Natera, Inc. and GeneDx Holdings Corp. have outperformed the market and beaten analysts expectations. Natera's oncology tests driving revenue growth and GeneDx focusing on newborn rare disease diagnostics. Both firms have been improving financial metrics, with Natera showing strong revenue growth driven by oncology tests in Q2 2024, while GeneDx achieved profitability in Q3 2024.

Natera And GeneDx: Outperforming Market Powered By Precision Medicines Tailwinds

GeneDx Holdings Corp. stock has risen by a scarcely believable >3,000% across the past year. The company provides exome sequencing products that can be used to search for and diagnose hundreds of genetic conditions. The company's Q3 earnings led to a >50% uplift in the share price this week, with ~$287 revenues pledged for 2024, and a gross margin of >60%.

GeneDx Holdings: Phenomenal Gains, More Upside Potential In Medium Term

GeneDx Holdings Corp. (NASDAQ:WGS ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Sabrina Dunbar - Investor Relations Katherine Stueland - President and Chief Executive Officer Kevin Feeley - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen William Bonello - Craig Hallum Capital Group Mark Massaro - BTIG Matthew Sykes - Goldman Sachs Group, Inc. Brandon Couillard - Wells Fargo Securities Matthew Stanton - Jefferies Operator Thank you for standing by, and welcome to the GeneDx Third Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode and after the speaker's presentation we will have a question-and-answer session Keep in mind that this call is being recorded.

GeneDx Holdings Corp. (WGS) Q3 2024 Earnings Call Transcript

GeneDx Holdings WGS stock is trading higher on Tuesday.

Genetic Testing Firm GeneDx Reports Narrower Q3 Loss As Revenues Surge, Lifts Annual Guidance

GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to loss of $0.82 per share a year ago.

GeneDx Holdings Corp. (WGS) Tops Q3 Earnings and Revenue Estimates

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the third quarter of 2024.

GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that JAMA, the Journal of the American Medical Association, published peer-reviewed research from the GUARDIAN (Genomic Uniform-screening Against Rare Diseases In All Newborns) study, the largest study of its kind to explore the utility of whole genome sequencing (WGS) to identify 255 early onset genetic conditions in newborns from a diverse populatio.

Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening

GeneDx Holdings Corp. leverages its genomic and data science expertise to provide precise medical diagnostics, focusing on rare diseases and pediatric exome/genome testing. The company's second-quarter performance exceeded expectations, driven by over 125% year-over-year growth in its whole exome and genome business, now 74% of total revenue. GeneDx reduced its quarterly cash burn significantly and anticipates profitability by 2025, with increasing reimbursement rates and expanding Medicaid coverage boosting revenue.

GeneDx Holdings: Stock To Keep Outperforming As Business Momentum Persists

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it has provided genomic newborn screenings (gNBS) for more than 14,000 infants through its participation in groundbreaking research studies which aim to explore the clinical utility and implementation of utilizing genome sequencing to expand standard newborn screening (NBS). Through these studies, GeneDx has conducted more gNBS than any other lab and.

GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx today announced it will release financial results for the third quarter of 2024 before the market opens on Tuesday, October 29, 2024.

GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that the compensation committee of GeneDx's board of directors granted restricted stock units (“RSUs”).

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GeneDx is helping patients navigate through the "diagnostic odyssey" with DNA sequencing. The biotech stock is on its own odyssey.

GeneDx Stock Rocketed 1310% In Dramatic Turnaround Powered By DNA Analytics

GeneDx Holdings is poised for profitability in the near future. GeneDx is benefitting from increased volume and improved average reimbursement rates. The company's double-digit revenue growth and soon to be achieved profitability are likely positive drivers for the stock.

News for GeneDx Holdings Corp Stock (WGS)